OverviewSuggest Edit

Homology is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. This non-nuclease-based approach offers clear advantages in its precision, efficiency and on-target in vivo editing of genetic mutations. Homology obtained an exclusive worldwide license to this technology platform, which is based on the pioneering research of Saswati Chatterjee, Ph.D., Professor of Virology at the Beckman Research Institute at the City of Hope in California, member of the Recombinant DNA Advisory Committee (RAC) to the Office of the Director, National Institutes of Health (NIH) and former charter member of the Therapeutic Approaches to Genetic Diseases Study Section of the NIH. Dr. Chatterjee and her team led the first adeno-associated virus (AAV) vector-mediated gene transfer studies into human hematopoietic stem cells and subsequently identified and isolated a series of naturally-occurring AAVs from human CD34+ cells.
TypePublic
Founded2015
HQBedford, MA, US
Websitehomologymedicines.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2018)124
Revenue (FY, 2020)$2.7 M(+63%)
Share Price (Sept 2021)$8.2
Cybersecurity ratingFMore

Key People/Management at Homology Medicines

Kush M. Parmar

Kush M. Parmar

Director
Brad Smith

Brad Smith

Chief Financial Officer
Steven Gillis

Steven Gillis

Director
Richard Gregory

Richard Gregory

Director
Albert Seymour

Albert Seymour

Chief Scientific Officer
Matthew Patterson

Matthew Patterson

Director
Show more

Homology Medicines Office Locations

Homology Medicines has an office in Bedford
Bedford, MA, US (HQ)
1 Patriots Park
Show all (1)

Homology Medicines Financials and Metrics

Homology Medicines Revenue

Homology Medicines's revenue was reported to be $2.7 m in FY, 2020
USD

Revenue (FY, 2020)

2.7m

Net income (FY, 2020)

(128.7m)

EBIT (FY, 2020)

(130.3m)

Market capitalization (22-Sept-2021)

468.1m

Closing stock price (22-Sept-2021)

8.2

Cash (31-Dec-2020)

217.4m

EV

266.1m
Homology Medicines's current market capitalization is $468.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.7m1.7m2.7m

General and administrative expense

4.3m8.3m17.3m22.2m32.6m

R&D expense

5.7m21.4m47.9m89.4m100.4m

Operating expense total

10.0m29.7m65.2m111.6m133.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020

Revenue

823.4k926.5k954.1k270.0k588.0k

General and administrative expense

3.8m4.5m3.8m4.9m7.8m

R&D expense

8.0m10.3m13.4m20.5m29.3m

Operating expense total

11.8m14.8m17.2m25.4m37.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

11.4m51.6m38.2m53.8m217.4m

Prepaid Expenses

481.8k1.9m6.9m4.2m2.1m

Current Assets

12.0m131.6m221.7m266.6m219.6m

PP&E

2.0m3.2m35.6m42.7m37.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020

Cash

46.2m95.0m36.0m40.8m143.4m

Prepaid Expenses

3.7m6.1m8.3m2.5m3.4m

Current Assets

120.4m261.6m245.9m190.5m238.3m

PP&E

3.8m6.9m20.7m41.0m42.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(8.0m)(30.0m)(57.2m)(103.9m)(128.7m)

Depreciation and Amortization

239.8k684.2k1.3m6.3m8.0m

Accounts Payable

518.0k1.7m4.4m(4.5m)2.5m

Cash From Operating Activities

(8.5m)6.5m(42.6m)(91.4m)(94.3m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020

Net Income

(10.5m)(23.4m)(38.2m)(23.9m)(35.3m)

Depreciation and Amortization

220.6k457.8k725.8k1.3m1.9m

Accounts Payable

510.9k2.6m(571.2k)(85.0k)4.8m

Cash From Operating Activities

(11.0m)(20.8m)(34.5m)(17.9m)(25.8m)
USDFY, 2016

Financial Leverage

-1.4 x
Show all financial metrics

Homology Medicines Cybersecurity Score

Cybersecurity ratingPremium dataset

F

59/100

SecurityScorecard logo

Homology Medicines Online and Social Media Presence

Embed Graph

Homology Medicines News and Updates

Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights

- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021-

Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board

- ASGCT President and Entrepreneur Takes Leadership Role on SAB as Company Expects to Have Three Clinical Programs in 2021 -

Homology Medicines to Participate in Upcoming Investor Conferences

BEDFORD, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation in fireside chats at the following virtual conferences:

Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model

- Proof of Concept Data for New GTx-mAb Platform to Be Featured at ASGCT Along With Presentations From Multiple Programs -

Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting

- Data From Company’s PKU and Hunter Syndrome Gene Therapy Programs Featured in Presentations -
Show more

Homology Medicines Frequently Asked Questions

  • When was Homology Medicines founded?

    Homology Medicines was founded in 2015.

  • Who are Homology Medicines key executives?

    Homology Medicines's key executives are Kush M. Parmar, Brad Smith and Steven Gillis.

  • How many employees does Homology Medicines have?

    Homology Medicines has 124 employees.

  • What is Homology Medicines revenue?

    Latest Homology Medicines annual revenue is $2.7 m.

  • What is Homology Medicines revenue per employee?

    Latest Homology Medicines revenue per employee is $21.8 k.

  • Who are Homology Medicines competitors?

    Competitors of Homology Medicines include GeneDx, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and Ambry Genetics.

  • Where is Homology Medicines headquarters?

    Homology Medicines headquarters is located at 1 Patriots Park, Bedford.

  • Where are Homology Medicines offices?

    Homology Medicines has an office in Bedford.

  • How many offices does Homology Medicines have?

    Homology Medicines has 1 office.